SCHEMBL16562148

SCHEMBL16562148

O=C(NCCc1ccccc1)C(=O)Nc1ccc(Cl)cc1

nearest known ligand 0.76

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CNR1 P21554 8/20 0.76
SMN1; SMN2 Q16637 3/20 0.76
NPC1 O15118 1/20 0.76
RAB9A P51151 1/20 0.76
MEN1 O00255 4/20 0.67
KMT2A Q03164 4/20 0.67
MAPT P10636 3/20 0.67
PLAAT3 P53816 2/20 0.65
PLAAT5 Q96KN8 2/20 0.65
PLAAT2 Q9NWW9 2/20 0.65
PLAAT4 Q9UL19 2/20 0.65
CYP1A2 P05177 1/20 0.63
CYP2D6 P10635 1/20 0.63
CYP2C19 P33261 1/20 0.63
POLB P06746 1/20 0.60
LMNA P02545 2/20 0.59
L3MBTL1 Q9Y468 1/20 0.57
TAAR1 Q96RJ0 1/20 0.57
ALDH1A1 P00352 1/20 0.56
HTT P42858 1/20 0.56

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16562213 0.92 CNR1 (0.73) CNR1SMN1; SMN2NPC1RAB9ACYP1A2
SCHEMBL3413251 0.89 KMT2A (0.71) CNR1SMN1; SMN2NPC1RAB9AMEN1
SCHEMBL16562184 0.87 CNR1 (0.78) CNR1SMN1; SMN2NPC1RAB9AMEN1
SCHEMBL16562056 0.87 CNR1 (0.66) CNR1SMN1; SMN2NPC1RAB9AMAPT
SCHEMBL4894746 0.86 CNR1 (1.00) CNR1SMN1; SMN2NPC1RAB9AMEN1
SCHEMBL16562263 0.85 CNR1 (0.77) CNR1SMN1; SMN2NPC1RAB9AMEN1
SCHEMBL16562062 0.85 CNR1 (0.77) CNR1SMN1; SMN2NPC1RAB9AMAPT
SCHEMBL16562270 0.85 CNR1 (0.77) CNR1SMN1; SMN2NPC1RAB9ACYP1A2
SCHEMBL16562099 0.84 CNR1 (0.79) CNR1SMN1; SMN2NPC1RAB9AMEN1
SCHEMBL17919329 0.82 CNR1 (0.79) CNR1SMN1; SMN2MEN1KMT2AMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9789096-B2 Methods and compositions for selective and targeted cancer therapy BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) 2017-10-17 US disclosed
US-20160200695-A1 Methods and Compositions for Selective and Targeted Cancer Therapy BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) 2016-07-14 US disclosed
WO-2015035051-A1 METHODS AND COMPOSITIONS FOR SELECTIVE AND TARGETED CANCER THERAPY BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) 2015-03-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160200695-A1 Methods and Compositions for Selective and Targeted Cancer Therapy NCOA4, SREBF1, ACOX1 CNR1 1450/4885SMN1; SMN2 3069/4885NPC1 840/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.